Market Analysts Eye Rare Disease Drug Development as the FDA Asks for Public Comments on Rare Disease Cures Program
December 19, 2022
The US Food and Drug Administration (FDA) released a request for public comments last week on its Accelerating Rare Disease Cures Program, signaling growing market interest to Wall Street analysts. The announcement comes as therapeutics for rare diseases account for over half of novel drug approvals in the US. Comments must be submitted to the agency before January 31st, 2023.
According to , “For analysts at SVB Securities, favorable signs can be seen in the recent FDA approvals of new gene therapies from bluebird bio for beta thal and CALD, CSL’s hemophilia B gene therapy Hemgenix, Ferring’s new gene therapy for bladder cancer, as well as FDA’s decision to not conduct an adcomm for BioMarin’s gene therapy for hemophilia A.”
To read more, click here.
(Source: Endpoints News, December 19th, 2022)